Securities code: Sichuan Huiyu Pharmaceutical Co.Ltd(688553) securities abbreviation: Sichuan Huiyu Pharmaceutical Co.Ltd(688553) Announcement No.: 2022024 Sichuan Huiyu Pharmaceutical Co.Ltd(688553)
Application for comprehensive credit from banks and other financial institutions in 2022
Announcement of quota
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Important content tips:
Sichuan Huiyu Pharmaceutical Co.Ltd(688553) (hereinafter referred to as “the company”) and its wholly-owned subsidiaries intend to apply to banks and other financial institutions for a comprehensive credit line of no more than 500 million yuan in total.
This matter falls within the decision-making authority of the board of directors and does not need to be submitted to the general meeting of shareholders for deliberation.
On April 6, 2022, the company held the 22nd Meeting of the first board of directors, deliberated and adopted the proposal on the company’s application for comprehensive credit line from banks and other financial institutions in 2022. Relevant matters are hereby announced as follows:
In order to meet the needs of the company’s operation and development, the company and its wholly-owned subsidiaries plan to apply for comprehensive credit with a limit of no more than RMB 500 million from banks and their branches and other financial institutions in the form of land and real estate mortgage, accounts receivable pledge, bill pledge and credit. The scope of credit business includes but is not limited to credit, loan, bill, mortgage, financing Letter of guarantee, etc. (the specific business type, amount and period shall be subject to the relevant contracts actually signed).
The above credit line is not equal to the actual financing amount of the company. The actual financing amount should be within the credit line and subject to the actual financing amount between the bank and the company. The specific financing amount will be determined according to the actual needs of the company’s working capital. The validity period of this application for comprehensive credit is 12 months from the date of deliberation and approval by the board of directors. Within the credit term, the credit line can be recycled. In order to improve work efficiency, it is proposed to authorize the company’s management to handle relevant procedures and sign relevant business contracts and other relevant documents on behalf of the company within the above comprehensive credit line.
It is hereby announced.
Sichuan Huiyu Pharmaceutical Co.Ltd(688553) board of directors April 7, 2022
